Literature DB >> 19424055

No evidence of a change in HIV-1 virulence since 1996 in France.

Pénélope Troude1, Marie-Laure Chaix, Laurent Tran, Christiane Deveau, Rémonie Seng, Jean-François Delfraissy, Christine Rouzioux, Cécile Goujard, Laurence Meyer.   

Abstract

OBJECTIVE: We investigated temporal trends in the CD4 cell count and in plasma HIV RNA and total HIV DNA levels measured at the time of primary HIV infection, as proxies for HIV-1 virulence, taking changes in patient characteristics into account.
DESIGN: We studied 903 patients enrolled during primary HIV infection in the French multicenter ANRS PRIMO cohort from 1996 to 2007.
METHODS: Associations between the year of primary HIV infection and the values of the three markers were tested with regression models. The year of primary HIV infection was first introduced as a restricted cubic splines function in a regression model in order to explore the shape of the associations, and then as a continuous/categorical variable. The following confounders were considered in multiple regression analysis: time since infection and age (introduced as restricted cubic spline functions), sex, place of birth (Africa vs. others), symptomatic primary HIV infection, smoking, and virus-related factors (subtype B vs. non-B, and drug resistance mutations).
RESULTS: Multivariate analysis showed no temporal trends in the CD4 cell count (square-root) or in HIV-1 RNA and DNA levels (log10) measured at the time of primary HIV infection. We observed the well described associations between the prognostic markers and the time since infection, sex, symptomatic primary HIV infection, and smoking.
CONCLUSION: The CD4 cell count and HIV RNA and DNA levels measured at the time of primary HIV-1 infection remained stable across 12 consecutive years (1996-2007) in the ANRS PRIMO cohort, suggesting no major change in virulence, after taking into account changes in patient characteristics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424055     DOI: 10.1097/QAD.0b013e32832b51ef

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  19 in total

1.  Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Authors:  D Noah Sather; Sara Carbonetti; Jenny Kehayia; Zane Kraft; Iliyana Mikell; Johannes F Scheid; Florian Klein; Leonidas Stamatatos
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

2.  Immune-mediated attenuation of HIV-1.

Authors:  Denis R Chopera; Jaclyn K Wright; Mark A Brockman; Zabrina L Brumme
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

3.  The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

Authors:  Christine M Hogan; Victor Degruttola; Xin Sun; Susan A Fiscus; Carlos Del Rio; C Bradley Hare; Martin Markowitz; Elizabeth Connick; Bernard Macatangay; Karen T Tashima; Beatrice Kallungal; Rob Camp; Tia Morton; Eric S Daar; Susan Little
Journal:  J Infect Dis       Date:  2011-12-15       Impact factor: 5.226

4.  Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.

Authors:  Joshua T Herbeck; Viktor Müller; Brandon S Maust; Bruno Ledergerber; Carlo Torti; Simona Di Giambenedetto; Luuk Gras; Huldrych F Günthard; Lisa P Jacobson; James I Mullins; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

5.  Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.

Authors:  Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

6.  Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.

Authors:  Anne-Sophie Liovat; Marie-Anne Rey-Cuillé; Camille Lécuroux; Béatrice Jacquelin; Isabelle Girault; Gaël Petitjean; Yasmine Zitoun; Alain Venet; Françoise Barré-Sinoussi; Pierre Lebon; Laurence Meyer; Martine Sinet; Michaela Müller-Trutwin
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

7.  X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

Authors:  Jade Ghosn; Julie Galimand; Stéphanie Raymond; Laurence Meyer; Christiane Deveau; Cécile Goujard; Jacques Izopet; Christine Rouzioux; Marie-Laure Chaix
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

8.  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Authors:  Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

Review 9.  HIV-1 dynamics: a reappraisal of host and viral factors, as well as methodological issues.

Authors:  Heather A Prentice; Jianming Tang
Journal:  Viruses       Date:  2012-10-10       Impact factor: 5.048

10.  Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.

Authors:  Karen Champenois; Anthony Cousien; Lise Cuzin; Stéphane Le Vu; Sylvie Deuffic-Burban; Emilie Lanoy; Karine Lacombe; Olivier Patey; Pascal Béchu; Marcel Calvez; Caroline Semaille; Yazdan Yazdanpanah
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.